Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Seoul
Clinical trial register · South Korea

Clinical Trials in Seoul, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 62 Busan 19 Daegu 14 Seongnam 13 Goyang-si 12
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca195 Seoul National University Hospital183 Yonsei University143 Samsung Medical Center142 Merck Sharp & Dohme LLC111 Clear sponsor filter
Site location
Seoul62 Busan19 Daegu14 Seongnam13 Goyang-si12
All 27 locations
Target enrolment
to

Trials with a site in Seoul

62 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Recruiting
AbbVie
Phase 2/3
660
Seongnam-si, Seoul
2026-06-30
Recruiting
AbbVie
Phase 3
990
Busan, Incheon, Seongnam, Suwon, Hwasun-gun, Seoul
2026-05-22
Recruiting
AbbVie
Phase 1
18
Seoul
2026-05-20
Recruiting
AbbVie
Phase 2/3
900
Seoul
2026-04-30
Recruiting
AbbVie
Phase 2
165
Busan, Bucheon-si, Seongnam-si, Seoul
2026-01-23
Recruiting
AbbVie
Phase 2/3
490
Goyang-si, Cheongju-si, Seoul
2025-12-10
Recruiting
AbbVie
Phase 2
100
Seoul
2025-12-01
Recruiting
AbbVie
Phase 2
180
Goyang-si, Cheongju-si, Seoul
2025-11-25
Recruiting
AbbVie
Phase 2
400
Goyang-si, Seongnam-si, Seoul
2025-11-13
Recruiting
AbbVie
Phase 2
140
Seoul
2025-09-02
Recruiting
AbbVie
Observational
2,795
Seoul
2025-09-02
Recruiting
AbbVie
Phase 2/3
854
Busan, Cheongju-si, Seoul
2025-08-03
Recruiting
AbbVie
Phase 3
120
Yangsan, Seoul
2025-07-28
Recruiting
AbbVie
Phase 2
180
Cheonan-si, Suwon, Seoul
2025-06-20
Active, closed
AbbVie
Phase 3
573
Busan, Daegu, Daejeon, Seongnam-si, Suwon, Gwangju, Seoul
2025-06-17
Recruiting
AbbVie
Phase 2
110
Goyang-si, Seongnam, Seongnam-si, Daegu, Seoul
2025-05-28
Active, closed
AbbVie
Phase 3
468
Hwaseong, Seoul
2025-02-10
Active, closed
AbbVie
Phase 2
150
Goyang-si, Hwasun-gun, Seoul
2025-01-20
Active, closed
AbbVie
Phase 2
83
Ansan-si, Bucheon-si, Seoul
2024-12-19
Active, closed
AbbVie
Phase 2
74
Seongnam-si, Seoul
2024-11-08
Recruiting
AbbVie
Phase 2
590
Busan, Daejeon, Seoul, Daegu
2024-09-04
Recruiting
AbbVie
Phase 3
675
Ansan-si, Bucheon-si, Seoul
2024-08-19
Recruiting
AbbVie
Phase 3
110
Seoul
2024-08-08
Active, closed
AbbVie
Phase 3
1,400
Busan, Cheonan-si, Ansan-si, Seongnam, Seoul
2024-06-27
Recruiting
AbbVie
Phase 3
200
Ansan-si, Bucheon-si, Suwon, Seoul
2024-06-14
Active, closed
AbbVie
Phase 3
421
Seoul, Ulsan
2024-05-19
Active, closed
AbbVie
Phase 2
156
Busan, Daejeon, Seoul
2024-03-23
Active, closed
AbbVie
Phase 3
614
Daejeon, Bucheon-si, Suwon, Seoul
2023-12-19
Recruiting
AbbVie
Phase 3
110
Seoul, Daegu
2023-12-11
Active, closed
AbbVie
Phase 3
289
Busan, Daejeon, Suwon, Seoul, Daegu
2023-11-15
Active, closed
AbbVie
Phase 2
280
Hwasun-gun, Seoul
2023-11-12
Recruiting
AbbVie
Phase 1
325
Busan, Jinju, Cheongju-si, Seoul
2023-11-09
Active, closed
AbbVie
Phase 3
122
Seoul, Daegu
2023-11-06
Recruiting
AbbVie
Phase 3
1,500
Busan, Daegu, Daejeon, Seongnam-si, Incheon, Jeonju, Seoul
2023-10-11
Active, closed
AbbVie
Phase 2
130
Seongnam, Seongnam-si, Hwasun-gun, Seoul
2023-09-21
Active, closed
AbbVie
Phase 3
1,014
Cheonan-si, Gwangju, Seoul
2023-07-25
Active, closed
AbbVie
Phase 3
1,328
Ansan-si, Seongnam, Seoul
2023-06-21
Active, closed
AbbVie
Phase 1
39
Seoul
2023-04-26
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
AbbVie
Phase 1
78
Seoul
2023-04-04
Active, closed
AbbVie
Phase 3
520
Goyang-si, Seongnam, Seongnam-si, Daegu, Seoul
2023-03-15
Active, closed
AbbVie
Phase 1
288
Goyang-si, Seongnam, Hwasun-gun, Seoul
2022-12-05
Recruiting
AbbVie
Phase 3
768
Goyang-si, Seongnam, Suwon, Jinju, Yangsan, Cheongju-si, Seoul
2022-03-25
Recruiting
AbbVie
Phase 1
694
Goyang-si, Seongnam, Seoul
2021-11-01
Active, closed
AbbVie
Phase 1
520
Busan, Seongnam, Jinju, Cheongju-si, Seoul
2021-10-13
Active, closed
AbbVie
Phase 1
81
Goyang-si, Seoul
2021-02-23
Active, closed
AbbVie
Phase 3
527
Junggu, 서구, Seoul
2020-09-30
Active, closed
AbbVie
Phase 3
531
Busan, Seongnam-si, Seoul
2020-09-10
Active, closed
AbbVie
Phase 3
330
Busan, Incheon, Seoul
2020-08-31
Active, closed
AbbVie
Phase 3
56
Seoul
2020-02-04
Active, closed
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
DrugsVenclexta·Venetoclax
AbbVie
Phase 3
165
Seoul
2019-09-06
Active, closed
AbbVie
Phase 3
964
Seoul, Daegu
2019-03-25
Active, closed
AbbVie
Phase 1
364
Incheon, Hwasun-gun, Seoul
2019-02-21
Active, closed
AbbVie
Phase 3
265
Incheon, Seoul, Ulsan
2018-10-22
Active, closed
AbbVie
Phase 2
270
Goyang-si, Seongnam, Suwon, Yangsan, Incheon, Hwasun-gun, Cheongju-si, Seoul
2018-10-10
Active, closed
AbbVie
Phase 3
1,242
Busan, Daejeon, Guri-si, Seongnam, Suwon, Seoul, Daegu
2018-08-28
Active, closed
AbbVie
Phase 3
1,336
Busan, Daegu, Daejeon, Guri-si, Seongnam-si, Suwon, Seoul
2018-04-09
Active, closed
AbbVie
Phase 3
747
Busan, Daegu, Guri-si, Seongnam-si, Dongjak-gu, Seoul
2018-03-21
Active, closed
AbbVie
Phase 1
163
Seoul
2017-02-22
Active, closed
AbbVie
Phase 3
443
Seoul
2017-02-02
Active, closed
AbbVie
Phase 3
950
Busan, Guri-si, Seongnam, Suwon, Seoul, Daegu
2017-01-31
Active, closed
AbbVie
Phase 3
1,629
Daegu, Junggu, Gwangju, Seongdong-gu, Seoul
2015-12-01
Active, closed
AbbVie
Phase 1
237
Suwon, Seoul
2014-01-15
Rows per page Showing 1–62 of 62
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/seoul

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 62 of those studies with a site in Seoul that also match the filters currently applied.

How many clinical trials are recruiting in Seoul?

24 of the 62 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 38 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Seoul), 62 studies
PhaseStudiesRecruitingShare
Phase 331850%
Phase 215824.2%
Phase 111317.7%
Phase 2/3446.5%
Observational111.6%

Most active sponsors

Lead sponsors with the most studies (Seoul)
Lead sponsorStudiesRecruiting
AbbVie6224
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.